^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    vistusertib (AZD2014)

    i
    Company:
    AstraZeneca
    Drug class:
    mTOR inhibitor, mTORC2 inhibitor
    Related drugs:
    Apply
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bicalutamide • leucovorin calcium • bendamustine • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • GSK2636771 • Zirabev (bevacizumab-bvzr) • defactinib (VS-6063) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Provenge (sipuleucel-T) • TQB2440 (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • BCD-178 (pertuzumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)
    A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer (MANTA) (NCT02216786)
    Phase 2
    Queen Mary University of London
    Completed
    Last update posted :
    12/02/2024
    Initiation :
    01/16/2014
    Primary completion :
    12/31/2021
    Completion :
    12/31/2021
    HER-2 • ER
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    everolimus • fulvestrant • vistusertib (AZD2014)
    Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (PASTOR) (NCT02599714)
    Phase 1
    AstraZeneca
    Completed
    Last update posted :
    06/06/2024
    Initiation :
    12/07/2015
    Primary completion :
    03/30/2018
    Completion :
    11/23/2023
    HER-2 • ER
    |
    ER positive • HER-2 negative
    |
    Ibrance (palbociclib) • fulvestrant • vistusertib (AZD2014)
    mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian (NCT02208375)
    Phase 1/2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    11/11/2014
    Primary completion :
    12/30/2025
    Completion :
    12/30/2025
    ER • PGR • BRCA • MUC16
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Truqap (capivasertib) • vistusertib (AZD2014)
    National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer (NCT02664935)
    Phase 2
    University of Birmingham
    Active, not recruiting
    Last update posted :
    05/13/2024
    Initiation :
    05/01/2015
    Primary completion :
    09/01/2024
    Completion :
    09/01/2024
    NKX2-1 • TP63
    |
    Xalkori (crizotinib) • Tagrisso (osimertinib) • Ibrance (palbociclib) • Imfinzi (durvalumab) • docetaxel • Koselugo (selumetinib) • Truqap (capivasertib) • fexagratinib (ABSK091) • ceralasertib (AZD6738) • sitravatinib (MGCD516) • vistusertib (AZD2014)
    Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY) (NCT02546661)
    Phase 1
    AstraZeneca
    Active, not recruiting
    Last update posted :
    03/12/2024
    Initiation :
    10/03/2016
    Primary completion :
    03/18/2020
    Completion :
    06/28/2024
    HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL
    |
    PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)
    Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) (NCT02730923)
    Phase 1/2
    Centre Leon Berard
    Active, not recruiting
    Last update posted :
    02/13/2024
    Initiation :
    04/01/2016
    Primary completion :
    11/01/2019
    Completion :
    12/01/2024
    ER • PGR • ABCB1
    |
    PGR positive
    |
    anastrozole • vistusertib (AZD2014)
    AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas (NCT02831257)
    Phase 2
    Massachusetts General Hospital
    Completed
    Last update posted :
    06/13/2022
    Initiation :
    08/31/2016
    Primary completion :
    05/31/2019
    Completion :
    10/01/2020
    NF2
    |
    NF2 mutation
    |
    vistusertib (AZD2014)
    AZD8186 First Time In Patient Ascending Dose Study (NCT01884285)
    Phase 1
    AstraZeneca
    Completed
    Last update posted :
    05/29/2020
    Initiation :
    07/09/2013
    Primary completion :
    03/31/2019
    Completion :
    02/07/2020
    HER-2 • ER • PGR • PTEN • PIK3CB
    |
    HER-2 negative • PIK3CB mutation
    |
    abiraterone acetate • AZD8186 • vistusertib (AZD2014)
    A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers (TORCMEK) (NCT02583542)
    Phase 1/2
    Queen Mary University of London
    Unknown status
    Last update posted :
    02/25/2020
    Initiation :
    06/01/2015
    Primary completion :
    03/01/2020
    Completion :
    03/01/2020
    EGFR • HER-2 • KRAS • BRAF • ALK • PIK3CA • MET • NRAS • PTEN • STK11 • NF1 • FGFR • mTOR
    |
    docetaxel • Koselugo (selumetinib) • sirolimus • vistusertib (AZD2014)
    Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer (CaNCaP02) (NCT02064608)
    Phase 1
    Cambridge University Hospitals NHS Foundation T...
    Completed
    Last update posted :
    07/17/2019
    Initiation :
    10/01/2014
    Primary completion :
    12/01/2016
    Completion :
    06/01/2018
    EIF4EBP1
    |
    vistusertib (AZD2014)
    Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy (RICTOR_SC) (NCT03166904)
    Phase 2
    Samsung Medical Center
    Withdrawn
    Last update posted :
    05/20/2019
    Initiation :
    03/01/2018
    Primary completion :
    06/01/2018
    Completion :
    07/31/2018
    RICTOR
    |
    RICTOR amplification
    |
    vistusertib (AZD2014)
    Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014 (NCT01026402)
    Phase 1
    AstraZeneca
    Completed
    Last update posted :
    02/11/2016
    Initiation :
    12/01/2009
    Primary completion :
    08/01/2014
    Completion :
    08/01/2014
    EIF4EBP1
    |
    vistusertib (AZD2014)